4results about "Androstane derivatives" patented technology

The present invention relates to a process for preparing (15α,16α,17β)-Estra-1,3,5(10)-triene-3,15,16,17-tetrol, also known as Estetrol, having the formula shown below:

The application discloses a method for constructing fluorine-containing compounds by decarboxylation of alkyl carboxylic acid catalyzed by ketone compounds. The method uses alkyl carboxylic acid with a structure as shown in formula as a reaction raw material, and performs reaction under the joint action of ketone compounds, fluorine-containing reagents and alkali to obtain fluorides shown in formula (1) and formula (2), wherein R 1 are respectively and independently selected from hydrogen, a heterocyclic ring, substituted or unsubstituted aryl, and substituted or unsubstituted hydrocarbyl; R 2 are respectively and independently selected from hydrogen, a heterocyclic ring, substituted or unsubstituted aryl, and substituted or unsubstituted hydrocarbyl; R 3 are respectively and independently selected from hydrogen, a heterocyclic ring, substituted or unsubstituted aryl, and substituted or unsubstituted hydrocarbyl. The reaction method has the advantages of low cost, mild conditions, high reaction efficiency, high yield and high selectivity, and the like. The ketone compounds are used to replace traditional metal catalysts, which can not only provide a fluorine-containing compound library with various structures for candidate drug screening, but also can be applied to positron emission tomography imaging.

The invention discloses a prototerpane type triterpenoid compound in rhizoma alismatis as well as an extraction method and application thereof, belongs to the field of traditional Chinese medicine extraction, and particularly relates to a prototerpane type triterpenoid compound which is separated from the rhizoma alismatis and is shown in general formulas (I)-(VI), an extraction method of the prototerpane type triterpenoid compound and application of the prototerpane type triterpenoid compound in preparation of anti-inflammatory drugs. The structural diversity of active substances in the rhizoma alismatis is further enriched, on the basis, a foundation is laid for carrying out related biological activity tests on subsequently obtained monomeric compounds, an active lead compound is provided for new drug development, and meanwhile, a theoretical basis is provided for deep research and development of dry rhizoma alismatis tuberous root medicinal materials.